Exciting Schedule of Presentations for BRIUMVI at AAN 2025
TG Therapeutics, Inc. (NASDAQ: TGTX) recently announced an exciting lineup of presentations showcasing data on its groundbreaking treatment, BRIUMVI (ublituximab), aimed at improving outcomes for patients with relapsing forms of multiple sclerosis (RMS). These presentations will take place at the American Academy of Neurology (AAN) annual meeting, which serves as a prime venue for health care professionals to discuss advancements in neurology.
Key Details on Presentation Schedule
The AAN 2025 annual meeting is scheduled for early April, where esteemed professionals will present new findings concerning the safety and efficacy of BRIUMVI. The event marks a significant opportunity for TG Therapeutics to highlight its research efforts and advances in treatment methodology. The abstracts detailing the findings will be accessible online through the AAN meeting’s official platform.
Performance Insights from TG Presentations
TG Therapeutics will feature several significant presentations promoting their research on BRIUMVI. The poster presentations scheduled include:
1. No Association Between Decreases in Serum Immunoglobulin (Ig) Levels Below Normal and Serious Infections:
- Date and Time: April 7, from 5:00 PM–6:00 PM PT
- Session: Disease-modifying Therapies: Real-world Evidence and Adverse Events 1
- Abstract Number: 4695/P017
- Lead Author: Dr. Bruce Cree, Weill Institute for Neurosciences
2. Evaluation of Infusion Tolerability:
- Date and Time: April 7, from 5:00 PM–6:00 PM PT
- Session: Disease-modifying Therapies: Real-world Evidence and Adverse Events 1
- Abstract Number: 5121/P015
- Lead Author: Dr. Ed Fox, TG Therapeutics
3. ENABLE Study Results:
- Date and Time: April 7, from 5:00 PM–6:00 PM PT
- Session: Disease-modifying Therapies: Real-world Evidence and Adverse Events 1
- Abstract Number: 4773/P014
- Lead Author: Dr. Ed Fox, TG Therapeutics
4. Five Years of Ublituximab in Multiple Sclerosis:
- Date and Time: April 9, from 8:00 AM–9:00 AM PT
- Session: Clinical and Translational Research in MS 1
- Abstract Number: 2928/P006
- Lead Author: Dr. Bruce Cree, Weill Institute for Neurosciences
Research Highlights and Outcomes
In addition to the scheduled presentations, the company will provide extensive access to the data post-event. Presentation insights will be shared on the company's official website, enhancing accessibility for interested parties and further celebrating their commitment to transparency and innovation in MS treatment.
Understanding BRIUMVI and its Impact
BRIUMVI, a powerful monoclonal antibody targeting CD20, significantly advances the treatment landscape for multiple sclerosis. Its unique formulation employs glycoengineering techniques to optimize patient outcomes, allowing effective B-cell depletion at lower doses. Through rigorous clinical trials, BRIUMVI has demonstrated a favorable safety profile, making a positive impact on many patients suffering from RMS.
The use of BRIUMVI represents a pivotal shift in how relapsing multiple sclerosis is managed, providing patients with novel therapeutic options that may alleviate symptoms and potentially delay disease progression. As TG Therapeutics continues its journey of innovation, the data presented at the AAN 2025 will surely contribute to a greater understanding of multiple sclerosis treatments and patient management.
Frequently Asked Questions
What is BRIUMVI?
BRIUMVI is a monoclonal antibody that targets CD20+ B-cells, designed to treat relapsing forms of multiple sclerosis.
When is the AAN 2025 Annual Meeting?
The AAN 2025 Annual Meeting runs from April 5 to April 9, 2025.
Who is leading the presentations for TG Therapeutics?
Dr. Bruce Cree and Dr. Ed Fox are among the lead authors presenting data related to BRIUMVI.
What will be discussed in the BRIUMVI presentations?
Presentations will cover the safety and efficacy of BRIUMVI, including real-world evidence regarding patient outcomes and infusion tolerability.
How can I access the presentation data?
Data will be accessible on the TG Therapeutics website following the event, ensuring public access to the findings.
